IRLA IRulya Therapeutics Inc.
Listings ·
Nasdaq told Quince Therapeutics its stockholders' equity was ($35,324,000), below the $10,000,000 minimum. The company has until October 15, 2026 to submit a compliance plan and has filed an initial listing application that would come with a name change.
The company says it needs more time to complete its 2025 annual report because of reduced headcount and negative Phase 3 results. It expects to file within the fifteen calendar day extension under Rule 12b-25.
Quince Therapeutics agreed to sell about $11.5 million of stock and warrants to institutional investors and three executives, and up to $10.4 million more depends on holders paying $1.20 per share.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $35.4 million | $18.6 million |
| Net income (loss) | -$84.0 million | -$56.8 million |
| Cash from operations | -$41.4 million | -$31.9 million |
| Cash and equivalents | $5.8 million | $6.2 million |
| Short-term investments | $11.9 million | $34.6 million |
Our latest story on this, dated Jun 13, 2025: "Quince Therapeutics (now IRulya) agrees to $11.5 million private placement". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 4, 2026: "Quince Therapeutics (now IRulya Therapeutics) gets Nasdaq stockholders' equity deficiency notice". The story links the filing or release it is based on. Read the story.
IRulya Therapeutics Inc. trades under the ticker IRLA on NASDAQ.
IRulya Therapeutics Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for IRulya Therapeutics Inc. is 1662774. Its filings are on SEC EDGAR.
1,017,063 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-14.
Our directory records IRulya Therapeutics Inc. under United States.
Our directory classifies IRulya Therapeutics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for IRulya Therapeutics Inc. is US22053A3059.
aibio.space lists IRulya Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
IRulya Therapeutics Inc. reported a net loss of $84.0 million for the fiscal year ended Dec 31, 2025, and used $41.4 million of cash in operations, per its annual report to the SEC.
$35.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
$116.0 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on IRulya Therapeutics, dated Sep 4, 2026: "Quince Therapeutics (now IRulya Therapeutics) gets Nasdaq stockholders' equity deficiency notice". Nasdaq told Quince Therapeutics its stockholders' equity was ($35,324,000), below the $10,000,000 minimum. The company has until October 15, 2026 to submit a compliance plan and has filed an initial listing application that would come with a name change. Source.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,5.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.01,3.02,5.02,5.03,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,8.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio